These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 27868150)

  • 21. Calcipotriene 0.005% and betamethasone dipropionate 0.064% combination topical suspension (Taclonex Scalp).
    Scheinfeld NS
    Skinmed; 2011; 9(3):179-80. PubMed ID: 21675498
    [No Abstract]   [Full Text] [Related]  

  • 22. Differential effects of phototherapy, adalimumab and betamethasone-calcipotriol on effector and regulatory T cells in psoriasis.
    Kotb IS; Lewis BJ; Barker RN; Ormerod AD
    Br J Dermatol; 2018 Jul; 179(1):127-135. PubMed ID: 29330859
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Calcipotriol counteracts betamethasone-induced decrease in extracellular matrix components related to skin atrophy.
    Norsgaard H; Kurdykowski S; Descargues P; Gonzalez T; Marstrand T; Dünstl G; Røpke M
    Arch Dermatol Res; 2014 Oct; 306(8):719-29. PubMed ID: 25027750
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment adherence and real-life effectiveness of topical therapy in patients with mild or moderate psoriasis: uptake of scientific evidence in clinical practice and dermatologists' preferences for alternative treatment options.
    Neri L; Miracapillo A
    G Ital Dermatol Venereol; 2015 Feb; 150(1):19-26. PubMed ID: 25521808
    [TBL] [Abstract][Full Text] [Related]  

  • 25. IL-17-producing CD8+ T lymphocytes from psoriasis skin plaques are cytotoxic effector cells that secrete Th17-related cytokines.
    Ortega C; Fernández-A S; Carrillo JM; Romero P; Molina IJ; Moreno JC; Santamaría M
    J Leukoc Biol; 2009 Aug; 86(2):435-43. PubMed ID: 19487306
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of psoriasis with a new combination of calcipotriol and betamethasone dipropionate: a flow cytometric study.
    van Rossum MM; van Erp PE; van de Kerkhof PC
    Dermatology; 2001; 203(2):148-52. PubMed ID: 11586014
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A new calcipotriol/betamethasone dipropionate formulation (Daivobet) is an effective once-daily treatment for psoriasis vulgaris.
    Kaufmann R; Bibby AJ; Bissonnette R; Cambazard F; Chu AC; Decroix J; Douglas WS; Lowson D; Mascaro JM; Murphy GM; Stymne B
    Dermatology; 2002; 205(4):389-93. PubMed ID: 12444337
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effectiveness of two-compound formulation calcipotriol and betamethasone dipropionate gel in the treatment of moderately severe scalp psoriasis: a systematic review of direct and indirect evidence.
    Bottomley JM; Taylor RS; Ryttov J
    Curr Med Res Opin; 2011 Jan; 27(1):251-68. PubMed ID: 21142838
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Kaempferol attenuates imiquimod-induced psoriatic skin inflammation in a mouse model.
    Liu C; Liu H; Lu C; Deng J; Yan Y; Chen H; Wang Y; Liang CL; Wei J; Han L; Dai Z
    Clin Exp Immunol; 2019 Dec; 198(3):403-415. PubMed ID: 31407330
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mixed treatment comparison of a two-compound formulation (TCF) product containing calcipotriol and betamethasone dipropionate with other topical treatments in psoriasis vulgaris.
    van de Kerkhof P; de Peuter R; Ryttov J; Jansen JP
    Curr Med Res Opin; 2011 Jan; 27(1):225-38. PubMed ID: 21142833
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness model of topical treatment of mild to moderate psoriasis vulgaris in Germany. A comparison of calcipotriol/betamethasone (Daivobet/Dovobet/Taclonex) once daily and a morning/evening non-fix combination of calcipotriol and betamethasone.
    Augustin M; Peeters P; Radtke M; Moehling U; Lapp C
    Dermatology; 2007; 215(3):219-28. PubMed ID: 17823519
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment.
    Tillack C; Ehmann LM; Friedrich M; Laubender RP; Papay P; Vogelsang H; Stallhofer J; Beigel F; Bedynek A; Wetzke M; Maier H; Koburger M; Wagner J; Glas J; Diegelmann J; Koglin S; Dombrowski Y; Schauber J; Wollenberg A; Brand S
    Gut; 2014 Apr; 63(4):567-77. PubMed ID: 23468464
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Distinctive downmodulation of plasmacytoid dendritic cell functions by vitamin D3 analogue calcipotriol.
    Suzuki T; Tatsuno K; Ito T; Sakabe JI; Funakoshi A; Tokura Y
    J Dermatol Sci; 2016 Oct; 84(1):71-79. PubMed ID: 27342039
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic equivalence of two formulations of calcipotriol-betamethasone ointment: a multicentre, randomized, double-blind study in adult patients with chronic plaque psoriasis.
    Habjanic N; Koytchev R; Yankova R; Kerec-Kos M; Grabnar-Peklar D
    Br J Dermatol; 2018 Nov; 179(5):1189-1191. PubMed ID: 29945295
    [No Abstract]   [Full Text] [Related]  

  • 35. The Effect of the Long-Term Calcipotriol/Betamethasone Dipropionate Local Therapy on Tissue Resident Memory Cells Markers in Psoriatic Eruptions.
    Kasprowicz-Furmańczyk M; Czerwińska J; Placek W; Owczarczyk-Saczonek A
    Int J Environ Res Public Health; 2022 Jul; 19(14):. PubMed ID: 35886201
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vitamin D analog calcipotriol suppresses the Th17 cytokine-induced proinflammatory S100 "alarmins" psoriasin (S100A7) and koebnerisin (S100A15) in psoriasis.
    Hegyi Z; Zwicker S; Bureik D; Peric M; Koglin S; Batycka-Baran A; Prinz JC; Ruzicka T; Schauber J; Wolf R
    J Invest Dermatol; 2012 May; 132(5):1416-24. PubMed ID: 22402441
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy, safety and quality of life of calcipotriol/betamethasone dipropionate (Dovobet) versus calcipotriol (Daivonex) in the treatment of psoriasis vulgaris: a randomized, multicentre, clinical trial.
    Saraceno R; Andreassi L; Ayala F; Bongiorno MR; Giannetti A; Lisi P; Martini P; Peris K; Peserico A; Chimenti S
    J Dermatolog Treat; 2007; 18(6):361-5. PubMed ID: 17934937
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Microcirculatory modifications of psoriatic lesions during topical therapy.
    Rosina P; Giovannini A; Gisondi P; Girolomoni G
    Skin Res Technol; 2009 May; 15(2):135-8. PubMed ID: 19622121
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Topical calcipotriene 0.005% and betamethasone dipropionate 0.064% maintains efficacy of etanercept after step-down dose in patients with moderate-to-severe plaque psoriasis: results of an open label trial.
    Kircik LH
    J Drugs Dermatol; 2011 Aug; 10(8):878-82. PubMed ID: 21818509
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet/Daivobet/Taclonex) in the treatment of psoriasis vulgaris.
    Kragballe K; Austad J; Barnes L; Bibby A; de la Brassinne M; Cambazard F; Fleming C; Heikkilä H; Jolliffe D; Peyri J; Svensson A; Toole J; Wozel G
    Br J Dermatol; 2006 Jun; 154(6):1155-60. PubMed ID: 16704648
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.